Champions Oncology financials
$4.79−2.84%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jul 31 | Q4 '26 Apr 30 | Q3 '26 Jan 31 | Q2 '26 Oct 31 | Q1 '26 Jul 31 | Q4 '25 Apr 30 | Q3 '25 Jan 31 | Q2 '25 Oct 31 | Q1 '25 Jul 31 | Q4 '24 Apr 30 | Q3 '24 Jan 31 | Q2 '24 Oct 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.2M | $13.8M | $16.6M | $15.0M | $14.0M | $12.4M | $17.0M | $13.5M | $14.1M | $14.0M | $12.0M | $11.6M |
| Gross profit | $7.7M | $7.0M | $7.7M | $7.8M | $6.0M | $5.1M | $10.4M | $6.1M | $7.0M | $6.8M | $4.2M | $5.0M |
| Gross margin | 50.5% | 50.8% | 46.7% | 51.7% | 42.9% | 41.1% | 61.2% | 44.9% | 49.7% | 48.2% | 34.7% | 42.8% |
| Operating income | -$409.0K | -$521.0K | -$187.0K | $185.0K | -$527.0K | -$1.7M | $4.5M | $732.0K | $1.3M | -$271.0K | -$2.6M | -$2.0M |
| Net income | -$426.0K | -$667.0K | -$279.0K | $268.0K | -$466.0K | -$1.8M | $4.5M | $728.0K | $1.3M | -$109.0K | -$2.5M | -$2.1M |
| Net margin | −2.8% | −4.8% | −1.7% | 1.8% | −3.3% | −14.9% | 26.4% | 5.4% | 9.3% | −0.8% | −21.1% | −17.9% |
| Diluted EPS | $-0.03 | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.13 | $0.31 | $0.05 | $0.09 | $-0.01 | $-0.19 | $-0.15 |
| EBITDA | -$95.0K | -$200.0K | $154.0K | $542.0K | -$169.0K | -$1.3M | $4.9M | $1.1M | $1.8M | $621.0K | -$2.1M | -$1.5M |
| Operating cash flow | -$492.0K | -$2.0M | -$1.3M | -$1.7M | $600.0K | $6.9M | $490.0K | -$283.0K | $311.0K | -$1.8M | -$919.0K | $589.0K |
| Free cash flow | -$547.0K | -$2.2M | -$1.4M | -$2.0M | $554.0K | $6.6M | $448.0K | -$377.0K | $311.0K | -$1.8M | -$1.0M | $510.0K |
| Diluted shares | 13.9M | 13.2M | 13.9M | 14.5M | 13.8M | 14.6M | 14.4M | 14.0M | 14.0M | 13.6M | 13.6M | 13.5M |
Balance sheet
| Period end | Jul 31 | Apr 30 | Jan 31 | Oct 31 | Jul 31 | Apr 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.4M | $4.9M | $7.1M | $8.5M | $10.3M | $9.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $33.3M | $27.0M | $28.4M | $30.2M | $30.5M | $32.3M |
| Total liabilities | $28.8M | $22.9M | $24.1M | $25.9M | $27.0M | $28.6M |
| Shareholders' equity | $4.5M | $4.1M | $4.4M | $4.2M | $3.5M | $3.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology